Rheumatoid arthritis (RA) is a chronic inflammatory disease that ultimately leads to the progressive destruction of cartilage and bone in numerous joints. There is mounting evidence for an important function of innate immunity in the pathogenesis of RA. Activation of cells by microbial components and also by endogenous molecules via Toll-like receptor (TLR) results in the production of a variety of proinflammatory cytokines, chemokines, and destructive enzymes, some of which can characteristically be found in RA.By immunohistochemistry we found elevated TLR2, 3, and 4 expressions in the rheumatoid synovium. In the synovial lining layer and at sites of invasion into cartilage, RA synovial fibroblasts (RASF) are the major cells expressing TLR2, 3, and 4. Stimulation of cultured RASF in vitro with the TLR2 ligand bacterial lipoprotein (bLP), the TLR3 ligand poly(I-C), and the TLR4 ligand LPS was shown to upregulate IL-6 as well as matrix metalloproteinases (MMPs) 1 and 3. These results suggest an important role for TLR2, 3, and 4 in the activation of synovial fibroblasts in RA leading to chronic inflammation and joint destruction. 
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease with progressive articular damage caused by inflammatory cells and synoviocytes. Cartilage RA synovial fibroblasts (RASF) must be considered key cells in mediating the destruction of cartilage and bone in the affected joints. They are mainly found in the synovial lining layer which is thickened and hyperplastic in RA ( ). Considering the important role of TLR signalling as a critical link between innate and adaptive immunity it has been proposed that a dysregulation in TLR signalling might be associated with autoimmune diseases, such as RA ( 4, 5 ).
To investigate whether TLR2, 3 and 4 are expressed in RA synovial tissues we performed immunohistochemistry on snap frozen RA synovial tissues with commercially available polyclonal antibodies. As non inflammatory controls we also stained synovial tissues derived from osteoarthritis (OA) patients. By this technique we found TLR2, 3 and 4 proteins to be broadly expressed in synovial tissues derived from RA patients ( 6, 7 ). In particular, there was a pronounced expression in the synovial lining layer. In comparison to RA tissues, TLR2, 3 and 4 protein expression was markedly lower in OA synovial tissues.
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The RA synovial lining layer is composed of activated synovial fibroblasts and macrophages.
To characterize the TLR3 expressing cells in the synovial lining layer, tissue sections were double stained for TLR3 and the macrophage marker CD68. The majority of cells expressing TLR3 did not stain for CD68, indicating that most synoviocytes expressing TLR3 were not macrophages but synovial fibroblasts ( 2 ).
It is known that IL-6 exerts stimulatory effects on T-and B-cells, thus favoring chronic inflammatory responses, whereas matrix metalloproteinases (MMPs) have been closely linked to the progressive destruction of articular cartilage in rheumatoid joints. To analyze whether TLR signaling might contribute to the elevated IL-6, MMP1 and MMP3 levels in the rheumatoid joint, RASF were isolated from RA synovial tissues and stimulated with the TLR2, 3 and 4 ligands. 24h after stimulation cell culture supernatants were collected and the cells were lysed in order to isolate total RNA. In the cell culture supernatants IL-6 levels were measured by a commercially available enzyme linked immunosorbent assay (ELISA) set.
Furthermore upregulation of MMP1 and MMP3 mRNA was determined by TaqMan Realtime PCR. We found a strong upregulation of IL-6, MMP1 and MMP3 by all three TLR ligands, with a most marked upregulation reached by the TLR3 ligand poly(I-C) ( 2, 8 ). These results document a strong proinflammatory and joint destructing role of TLR signalling pathways in the pathogenesis of RA and identify TLRs as potential therapeutic targets. 
Methods:
To analyze whether TLRs might play a role in the pathogenesis of RA the first step was to investigate whether TLRs are present in the rheumatoid synovium. Furthermore, TLR expression was compared between RA and non-inflammatory OA patients, in order to study the pathogenic relevance of TLR expression in RA. To obtain reliable results it is essential that tissue specimens obtained after surgery are immediately embedded in O.C.T compound and snap frozen in liquid nitrogen. 12. Apply AEC substrate-chromogen solution and incubate 2-5 min or until desired color intensity has developed.
Preparation of fresh
13. Rinse sections two times for 5 min with dH 2 O, shaking gently.
14. Counterstain the sections for 5-10 seconds with the hematoxylin counterstaining solution.
15. Rinse the slides under gently running tap water for 5 min (avoid a direct jet which may wash off or loosen the section).
16. Mount the sections using aqueous mounting medium such as glycerol gelatine.
Coverslip may be sealed with clear nail polish. (see Note 10)
An example of the results produced is shown in Figure 1 .
Double staining for TLR3 and CD68
Because TLR3 and CD68 specific antibodies are derived from different host species, the simultaneous staining method can be applied. Simultaneous staining is less time-consuming than the sequential method, since primary and secondary antibodies can be mixed together in two incubation steps.
1. Follow steps 1-4 according to the protocol 3.2.1: Fixation (1) and rehydration (2) of the tissue sections, followed by blocking the peroxidase activity (3) and blocking of unspecific binding (4).
2. Gently shake off excess blocking buffer and cover sections with TLR3 and CD68 specific antibodies (5 μg/ml anti-human TLR3 antibodies / 5 μg/ml mouse anti-human CD68 antibodies) or corresponding negative control antibodies (5 μg/ml goat IgGs / 5 μg/ml mouse IgG1) diluted in blocking buffer (TBS, 2% FBS). Replace the sections in the humidity chamber and incubate either at room temperature for 1 hour or overnight at 4°C. An example of the results produced is shown in Figure 3 .
IL-6 ELISA
To determine the levels of IL-6 protein in the cell supernatants by ELISA, use the OptEIA 
